Trials / Unknown
UnknownNCT03722875
SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery
A Single Arm Pilot Study of Programmed Cell Death Drotein 1 Antibody (PD-1） SHR-1210 Combined With Apatinib Mesylate in Patients With Intermediate And Advanced-Stage Hepatocellular Carcinoma After Radical Hepatectomy
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
SHR-1210 is a humanized anti-PD1 Immunoglobulin G4 (IgG4) monoclonal antibody. This is an open- label，single center ，non-randomized ，Single Arm Exploratory Study . This clinical study is an investigator-initiatedclini-cal trial（IIT ）.The objective of this study is to evaluate the efficacy and safety of adjuvant therapy with anti-PD-1 antibody SHR-1210 and apatinib in patients with Barcelona Clinic Liver Cancer (BCLC) B\&C stage hepatocellular carcinoma after surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1210 | SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. |
| DRUG | apatinib | Apatinib is a selective VEGFR2 inhibitor |
Timeline
- Start date
- 2018-12-01
- Primary completion
- 2019-03-01
- Completion
- 2020-03-01
- First posted
- 2018-10-29
- Last updated
- 2018-12-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03722875. Inclusion in this directory is not an endorsement.